Suppr超能文献

通过序列特异性组蛋白修饰因子对淋巴瘤致癌基因进行靶向表观遗传抑制可诱导弥漫性大B细胞淋巴瘤细胞凋亡。

Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL.

作者信息

Luo Hong, Schmidt Jennifer A, Lee Yi-Shan, Oltz Eugene M, Payton Jacqueline E

机构信息

a Department of Pathology and Immunology , Washington University School of Medicine , St. Louis , MO , USA.

出版信息

Leuk Lymphoma. 2017 Feb;58(2):445-456. doi: 10.1080/10428194.2016.1190973. Epub 2016 Jun 7.

Abstract

Alterations to the epigenetic landscape of diffuse large B-cell lymphoma (DLBCL) play a fundamental role in deregulating genes involved in normal lymphocyte differentiation. To determine whether targeted epigenetic therapy could reverse these pathogenic chromatin changes and suppress the expression of a lymphoma oncogene, we focused on BCL6, a transcriptional repressor whose aberrant expression is tightly linked to DLBCL proliferation and survival. We fused zinc-finger (ZF) domains specific for regulatory regions in the BCL6 locus to a repressive epigenetic modifier, the Kruppel-associated box (KRAB) repressor domain. Distinct ZF-KRAB fusions repressed the local chromatin landscape, suppressed BCL6 expression, significantly impaired DLBCL growth, and caused widespread cell death in a BCL6-dependent manner. Importantly, expression of ectopic BCL6 protein rescued ZF-KRAB-induced cell death, demonstrating the modifiers' specificity. We show that sequence-specific epigenetic modifiers can alter oncogene expression and induce apoptosis in cancer cells, underscoring their potential for future development as targeted epigenetic protein therapies.

摘要

弥漫性大B细胞淋巴瘤(DLBCL)表观遗传格局的改变在失调参与正常淋巴细胞分化的基因方面起着根本性作用。为了确定靶向表观遗传疗法是否能够逆转这些致病性染色质变化并抑制淋巴瘤癌基因的表达,我们聚焦于BCL6,一种转录抑制因子,其异常表达与DLBCL的增殖和存活紧密相关。我们将针对BCL6基因座调控区域的锌指(ZF)结构域与一种抑制性表观遗传修饰因子——克鲁ppel相关框(KRAB)抑制结构域融合。不同的ZF-KRAB融合体抑制了局部染色质格局,抑制了BCL6的表达,显著损害了DLBCL的生长,并以BCL6依赖的方式导致广泛的细胞死亡。重要的是,异位BCL6蛋白的表达挽救了ZF-KRAB诱导的细胞死亡,证明了这些修饰因子的特异性。我们表明,序列特异性表观遗传修饰因子可以改变癌基因表达并诱导癌细胞凋亡,突出了它们作为靶向表观遗传蛋白疗法未来发展的潜力。

相似文献

1
Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL.
Leuk Lymphoma. 2017 Feb;58(2):445-456. doi: 10.1080/10428194.2016.1190973. Epub 2016 Jun 7.
2
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
Blood. 2007 Sep 15;110(6):2067-74. doi: 10.1182/blood-2007-01-069575. Epub 2007 Jun 1.
3
The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
Blood. 2009 May 28;113(22):5536-48. doi: 10.1182/blood-2008-12-193037. Epub 2009 Mar 23.
4
BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas.
J Pathol. 2008 Mar;214(4):498-507. doi: 10.1002/path.2279.
6
miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.
Protein Cell. 2016 Dec;7(12):899-912. doi: 10.1007/s13238-016-0316-z. Epub 2016 Nov 4.
7
8
Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Oncotarget. 2016 Jan 19;7(3):3520-32. doi: 10.18632/oncotarget.6513.
9
AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.
Neoplasia. 2020 Mar;22(3):142-153. doi: 10.1016/j.neo.2020.01.002. Epub 2020 Feb 12.

引用本文的文献

1
Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.
EBioMedicine. 2019 Aug;46:170-183. doi: 10.1016/j.ebiom.2019.07.053. Epub 2019 Jul 26.
2
Emerging Gene Therapies for Genetic Hearing Loss.
J Assoc Res Otolaryngol. 2017 Oct;18(5):649-670. doi: 10.1007/s10162-017-0634-8. Epub 2017 Aug 16.

本文引用的文献

2
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.
Blood. 2015 Jan 1;125(1):22-32. doi: 10.1182/blood-2014-05-577189. Epub 2014 Dec 11.
3
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.
Nat Rev Drug Discov. 2014 Sep;13(9):673-91. doi: 10.1038/nrd4360. Epub 2014 Aug 18.
5
Engineered zinc-finger transcription factors activate OCT4 (POU5F1), SOX2, KLF4, c-MYC (MYC) and miR302/367.
Nucleic Acids Res. 2014 Jun;42(10):6158-67. doi: 10.1093/nar/gku243. Epub 2014 May 3.
6
Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis.
Trends Mol Med. 2014 Jun;20(6):343-52. doi: 10.1016/j.molmed.2014.03.001. Epub 2014 Mar 31.
7
A guide to genome engineering with programmable nucleases.
Nat Rev Genet. 2014 May;15(5):321-34. doi: 10.1038/nrg3686. Epub 2014 Apr 2.
8
KRAB-Zinc Finger Proteins: A Repressor Family Displaying Multiple Biological Functions.
Curr Genomics. 2013 Jun;14(4):268-78. doi: 10.2174/13892029113149990002.
9
Diffuse large B-cell lymphoma-treatment approaches in the molecular era.
Nat Rev Clin Oncol. 2014 Jan;11(1):12-23. doi: 10.1038/nrclinonc.2013.197. Epub 2013 Nov 12.
10
Developmental fate and cellular maturity encoded in human regulatory DNA landscapes.
Cell. 2013 Aug 15;154(4):888-903. doi: 10.1016/j.cell.2013.07.020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验